drugset / Trial / NCT07133802
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Phase 3
Not yet recruiting
6680 enrolled
Changchun BCHT Biotechnology Co.
Center for Disease Control and Prevention, Fujian · collabHubei Provincial Center for Disease Control and Prevention · collabZhejiang Provincial Center for Disease Control and Prevention · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Timeline
- Start
- 2025-08
- Primary completion
- 2026-03
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluMist | Vaccine | 0.2 ml | Intranasal |
Indications
No indication recorded.